These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 9730951)
1. GLP-1 action in L6 myotubes is via a receptor different from the pancreatic GLP-1 receptor. Yang H; Egan JM; Wang Y; Moyes CD; Roth J; Montrose MH; Montrose-Rafizadeh C Am J Physiol; 1998 Sep; 275(3):C675-83. PubMed ID: 9730951 [TBL] [Abstract][Full Text] [Related]
2. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. Luque MA; González N; Márquez L; Acitores A; Redondo A; Morales M; Valverde I; Villanueva-Peñacarrillo ML J Endocrinol; 2002 Jun; 173(3):465-73. PubMed ID: 12065236 [TBL] [Abstract][Full Text] [Related]
3. Dual glucagon recognition by pancreatic beta-cells via glucagon and glucagon-like peptide 1 receptors. Moens K; Flamez D; Van Schravendijk C; Ling Z; Pipeleers D; Schuit F Diabetes; 1998 Jan; 47(1):66-72. PubMed ID: 9421376 [TBL] [Abstract][Full Text] [Related]
4. Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signaling. Heller RS; Kieffer TJ; Habener JF Biochem Biophys Res Commun; 1996 Jun; 223(3):624-32. PubMed ID: 8687446 [TBL] [Abstract][Full Text] [Related]
5. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. Göke R; Fehmann HC; Linn T; Schmidt H; Krause M; Eng J; Göke B J Biol Chem; 1993 Sep; 268(26):19650-5. PubMed ID: 8396143 [TBL] [Abstract][Full Text] [Related]
6. Ligand-induced regulation of glucagon-like peptide-I receptor function and expression in insulin-secreting beta cells. Fehmann HC; Jiang J; Pitt D; Schweinfurth J; Göke B Pancreas; 1996 Oct; 13(3):273-82. PubMed ID: 8884849 [TBL] [Abstract][Full Text] [Related]
7. Mutations to the third cytoplasmic domain of the glucagon-like peptide 1 (GLP-1) receptor can functionally uncouple GLP-1-stimulated insulin secretion in HIT-T15 cells. Salapatek AM; MacDonald PE; Gaisano HY; Wheeler MB Mol Endocrinol; 1999 Aug; 13(8):1305-17. PubMed ID: 10446905 [TBL] [Abstract][Full Text] [Related]
8. Evidence that glucagon stimulates insulin secretion through its own receptor in rats. Kawai K; Yokota C; Ohashi S; Watanabe Y; Yamashita K Diabetologia; 1995 Mar; 38(3):274-6. PubMed ID: 7758872 [TBL] [Abstract][Full Text] [Related]
9. Reduction of the incretin effect in rats by the glucagon-like peptide 1 receptor antagonist exendin (9-39) amide. Kolligs F; Fehmann HC; Göke R; Göke B Diabetes; 1995 Jan; 44(1):16-9. PubMed ID: 7813808 [TBL] [Abstract][Full Text] [Related]
10. The human glucagon-like peptide-1 (GLP-1) receptor. Cloning and functional expression. Dillon JS; Wheeler MB; Leng XH; Ligon BB; Boyd AE Adv Exp Med Biol; 1997; 426():113-9. PubMed ID: 9544263 [No Abstract] [Full Text] [Related]
11. Interaction of glucagon-like peptide-I (GLP-I) and galanin in insulin (beta TC-1)- and somatostatin (RIN T3)-secreting cells and evidence that both peptides have no receptors on glucagon (INR1G9)-secreting cells. Fehmann HC; Janssen M; Göke B Acta Diabetol; 1995 Oct; 32(3):176-81. PubMed ID: 8590787 [TBL] [Abstract][Full Text] [Related]
12. Glucagon-like peptide-1 improves insulin and proinsulin binding on RINm5F cells and human monocytes. Ebinger M; Jehle DR; Fussgaenger RD; Fehmann HC; Jehle PM Am J Physiol Endocrinol Metab; 2000 Jul; 279(1):E88-94. PubMed ID: 10893327 [TBL] [Abstract][Full Text] [Related]
13. Interaction of GLP-I and leptin at rat pancreatic B-cells: effects on insulin secretion and signal transduction. Fehmann HC; Bode HP; Ebert T; Karl A; Göke B Horm Metab Res; 1997 Nov; 29(11):572-6. PubMed ID: 9479558 [TBL] [Abstract][Full Text] [Related]
14. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. Perry T; Lahiri DK; Chen D; Zhou J; Shaw KT; Egan JM; Greig NH J Pharmacol Exp Ther; 2002 Mar; 300(3):958-66. PubMed ID: 11861804 [TBL] [Abstract][Full Text] [Related]
15. Glucagon-like peptide-1 is a physiological incretin in rat. Wang Z; Wang RM; Owji AA; Smith DM; Ghatei MA; Bloom SR J Clin Invest; 1995 Jan; 95(1):417-21. PubMed ID: 7814643 [TBL] [Abstract][Full Text] [Related]
16. Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Holst JJ Expert Opin Emerg Drugs; 2004 May; 9(1):155-66. PubMed ID: 15155141 [TBL] [Abstract][Full Text] [Related]
17. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. Yusta B; Somwar R; Wang F; Munroe D; Grinstein S; Klip A; Drucker DJ J Biol Chem; 1999 Oct; 274(43):30459-67. PubMed ID: 10521425 [TBL] [Abstract][Full Text] [Related]
18. Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological incretin. Gault VA; O'Harte FP; Harriott P; Mooney MH; Green BD; Flatt PR Diabetologia; 2003 Feb; 46(2):222-30. PubMed ID: 12627321 [TBL] [Abstract][Full Text] [Related]
19. Truncated glucagon-like peptide-1 interacts with exendin receptors on dispersed acini from guinea pig pancreas. Identification of a mammalian analogue of the reptilian peptide exendin-4. Raufman JP; Singh L; Singh G; Eng J J Biol Chem; 1992 Oct; 267(30):21432-7. PubMed ID: 1328231 [TBL] [Abstract][Full Text] [Related]
20. Novel signal transduction and peptide specificity of glucagon-like peptide receptor in 3T3-L1 adipocytes. Montrose-Rafizadeh C; Yang H; Wang Y; Roth J; Montrose MH; Adams LG J Cell Physiol; 1997 Sep; 172(3):275-83. PubMed ID: 9284947 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]